Comprehensive approach to controlling chronic hepatitis B in China

키워드

참고문헌 (59)

1. Iannacone M, "Immunobiology and pathogenesis of hepatitis B virus infection", Nat Rev Immunol, 22, pp.19~32 (2022)
2. McMahon BJ, "Natural history of chronic hepatitis B", Clin Liver Dis, 14, pp.381~396 (2010)
3. "Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021"[URL]
4. Chen S, "The hepatitis B epidemic in China should receive more attention", Lancet, 391, pp.1572~ (2018)
5. Polaris Observatory Collaborators, "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016 : a modelling study", Lancet Gastroenterol Hepatol, 3, pp.383~403 (2018)
6. Cui F, "Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China", Emerg Infect Dis, 23, pp.765~772 (2017)
7. Kane MA, "The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization", Vaccine, 31(Suppl 9), pp.J15~J20 (2013)
8. Liang X, "Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination", Vaccine, 27, pp.6550~6557 (2009)
9. Hutin Y, "Improving hepatitis B vaccine timely birth dose coverage: lessons from five demonstration projects in China, 2005-2009", Vaccine, 31(Suppl 9), pp.J49~J55 (2013)
10. Chen S, "Combating hepatitis B and C by 2030 : achievements, gaps, and options for actions in China", BMJ Glob Health, 5, pp.e002306~ (2020)
11. Polaris Observatory Collaborators, "Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022 : a modelling study", Lancet Gastroenterol Hepatol, 8, pp.879~907 (2023)
12. Cui F, "Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China", Int J Epidemiol, 47, pp.1529~1537 (2018)
13. Liu Z, "Management algorithm for prevention of mother-to-child transmission of hepatitis B virus(2022)", J Clin Transl Hepatol, 10, pp.1004~1010 (2022)
14. Shan S, "Prevention of mother-to-child transmission of hepatitis B virus in the Western Pacific Region", Clin Liver Dis(Hoboken), 18, pp.18~21 (2021)
15. Wang AL, "Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China", Bull World Health Organ, 93, pp.52~56 (2015)
16. Pan CQ, "Tenofovir to prevent hepatitis B transmission in mothers with high viral load", N Engl J Med, 374, pp.2324~2334 (2016)
17. Yin X, "A realworld prospective study of mother-to-child transmission of HBV in China using a mobile health application(Shield 01)", J Clin Transl Hepatol, 8, pp.1~8 (2020)
18. Tanaka M, "Hepatitis B and C virus infection and hepatocellular carcinoma in China : a review of epidemiology and control measures", J Epidemiol, 21, pp.401~416 (2011)
19. Hamilton EM, "Correlates of chronic hepatitis B virus infection in the general adult population of China : Systematic review and meta-analysis", J Viral Hepat, 30, pp.470~488 (2023)
20. Wu Z, "Evaluation of immunization injection safety in China, 2010: achievements, future sustainability", Vaccine, 31(Suppl 9), pp.J43~J48 (2013)
21. Shan S, "How to control highly endemic hepatitis B in Asia", Liver Int, 38(Suppl 1), pp.122~125 (2018)
22. Bao Y, "Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China : A systematic review and meta-analysis", Int J Drug Policy, 70, pp.87~93 (2019)
23. Liu J, "Countdown to 2030 : eliminating hepatitis B disease, China", Bull World Health Organ, 97, pp.230~238 (2019)
24. Xiao J, "Global liver disease burdens and research trends : Analysis from a Chinese perspective", J Hepatol, 71, pp.212~221 (2019)
25. Zeng N, "Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China", Int J Infect Dis, 67, pp.58~64 (2018)
26. Sun Y, "New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment", Hepatology, 65, pp.1438~1450 (2017)
27. Kong Y, "Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir", J Viral Hepat, 26, pp.576~585 (2019)
28. Wu S, "On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis", Liver Int, 38, pp.1045~1054 (2018)
29. Wu X, "Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy", Hepatol Int, 15, pp.82~92 (2021)
30. Zhang W, "Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up", Medicine(Baltimore), 96, pp.e8454~ (2017)
31. Wang Q, "Validation of Baveno VII criteria for recompensation in entecavirtreated patients with hepatitis B-related decompensated cirrhosis", J Hepatol, 77, pp.1564~1572 (2022)
32. Wu X, "Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis", Hepatol Int, 15, pp.1318~1327 (2021)
33. You H, "Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)", J Clin Transl Hepatol, 11, pp.1425~1442 (2023)
34. Wang Y, "Control of chronic hepatitis B in China : Perspective of diagnosis and treatment", China CDC Wkly, 2, pp.596~600 (2020)
35. Hu C, "Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e Antigen-positive chronic hepatitis B : A real-world experience", Clin Ther, 43, pp.572~581 (2021)
36. Hu P, "HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog : New Switch Study", J Clin Transl Hepatol, 6, pp.25~34 (2018)
37. Chu JH, "Realworld study on HBsAg loss of combination therapy in HBeAgnegative chronic hepatitis B patients", J Viral Hepat, 29, pp.765~776 (2022)
38. Li M, "Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-Negative chronic hepatitis B after treatment with pegylated interferonα-2a", Virol Sin, 36, pp.311~320 (2021)
39. Jia J, "Real-world evidence for nucleoside", nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China : 52-week results, 2018, pp.23, 201~209
40. Hou JL, "Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24countries", Clin Gastroenterol Hepatol, 18, pp.457~467 (2020)
41. Qiu Q, "Impact of partial reimbursement on hepatitis B antiviral utilization and adherence", World J Gastroenterol, 21, pp.9588~9597 (2015)
42. Li M, "Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China", Lancet Reg Health West Pac, 16, pp.100249~ (2021)
43. [URL]
44. Zhao X, "Impact of national centralized drug procurement policy on antiviral utilization and expenditure for hepatitis B in China", J Clin Transl Hepatol, 10, pp.420~428 (2022)
45. Shan S, "Baseline characteristics and treatment patterns of the patients recruited to the China registry of hepatitis B", J Clin Transl Hepatol, 7, pp.322~328 (2019)
46. Li M, "Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China", J Dig Dis, 20, pp.467~475 (2019)
47. Cao G, "Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019 : findings from the Global Burden of Disease Study", Chin Med J(Engl), 135, pp.2049~2055 (2022)
48. Alberts CJ, "Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels : a systematic review", Lancet Gastroenterol Hepatol, 7, pp.724~735 (2022)
49. GBD 2019 Hepatitis B Collaborators, "Global, regional, and national burden of hepatitis B, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet Gastroenterol Hepatol, 7, pp.796~829 (2022)
50. Ling S, "Liver transplantation in patients with liver failure : Twenty years of experience from China", Liver Int, 42, pp.2110~2116 (2022)
51. Yue T, "Trends in the disease burden of HBV and HCV infection in China from 1990-2019", Int J Infect Dis, 122, pp.476~485 (2022)
52. Cao G, "Countdown on hepatitis B elimination by 2030 : the global burden of liver disease related to hepatitis B and association with socioeconomic status", Hepatol Int, 16, pp.1282~1296 (2022)
53. Liu Z, "Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021 : a systematic literature review and meta-analysis of 3740 studies and 231 million people", Gut, 72, pp.2354~2363 (2023)
54. Liu J, "Hepatitis B virus infection among 90 million pregnant women in 2853 Chinese counties, 2015-2020 : a national observational study", Lancet Reg Health West Pac, 16, pp.100267~ (2021)
55. Zhu X, "National EPI vaccination and hepatitis B vaccine coverage rate and the related factors : results from the 1999 nationwide survey", Chinese J Vacc Immun, 6, pp.193~197 (2000)
56. Nayagam S, "Investment case for a comprehensive package of interventions against hepatitis B in China : Applied modeling to help national strategy planning", Clin Infect Dis, 72, pp.743~752 (2021)
57. Toy M, "Costs and health impact of delayed implementation of a national hepatitis B treatment program in China", J Glob Health, 12, pp.04043~ (2022)
58. Su S, "Costeffectiveness of universal screening for chronic hepatitis B virus infection in China : an economic evaluation", Lancet Glob Health, 10, pp.e278~e287 (2022)
59. Zhang S, "Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China : an economic evaluation", Lancet Reg Health West Pac, 35, pp.100738~ (2023)

관련 논문AI추천